Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Element Materials Technology Enters the European Pharma Market with Major Life Sciences Acquisition

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Element Materials Technology (Element) has acquired Arch Sciences Group (Arch), a leading provider of analytical services and laboratory solutions to customers in the pharmaceuticals sector. As well as marking Element’s entry into the European pharmaceutical market, the move means that the life sciences end market is now the largest within the company.

Arch operates two divisions: the laboratory-based analytical services division, which directly supports drug development and new product regulatory approval cycles, and the technical laboratory solutions division, which supports a wide range of third-party laboratories.

The analytical services division, with laboratories in the UK and the US, provides a wide range of advanced analytical services with a global reputation for expertise in extractables and leachables testing services, and the testing of FDA-regulated consumer products.

Element Extractables and Leachables Testing

The technical laboratory solutions division delivers technical services, training through its global market-leading online CHROMacademy platform, method development and support, and consumable products covering the supply of specialist third party chromatography consumables. The technical laboratory solutions divisions also supports the creation of automated laboratory systems and instruments to improve the accuracy, efficiency and effectiveness of chemical analysis; sample preparation; and liquid handling.

With more than 170 employees across five locations in three countries, Arch holds a strong position in the market offering a comprehensive suite of specialist services and products that cater to customers’ testing and training requirements.

Jo Wetz, Element CEO, said: “Our acquisition of Arch complements our existing capabilities and expertise in the Americas after a period of significant growth there, and creates a strong platform to expand the pharmaceuticals segment of our life sciences business in Europe.

“Following the acquisitions of Avomeen and ALG in the last 12 months, and with this new commitment to growing the life sciences business in Europe, Element is rapidly developing its position as a full-service solutions provider to the life sciences segment, which is now the most significant end market for the Element Group.”

Scott Fletcher, CEO at Arch, commented: “We are looking forward to joining Element’s global family and tapping into its expertise across a wide range of services and geographies. As Element pushes forward with expansion of its life sciences offering, it’s an exciting time to enter the business, and we’re thrilled to be able to offer our expert capabilities to grow Element’s presence in Europe, the US and hopefully beyond.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine